Stoke - STOK Earnings growth forecast for next year
Market expectations for EPS growth indicate an investment stage, where the expansion of trials increases costs without immediate revenue. Stoke Therapeutics (STOK) relies on the TANGO gene modulation platform to create a closed therapeutic loop. The brand is valued by the community for its fight against childhood epilepsy. The value of -3.20 determines the latest valuation metric for future earnings.
Stoke Therapeutics, Inc. (STOK) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- issuer market value details:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Debt to Equity Stoke Therapeutics|STOK - Long-Term Liabilities to Equity|Short-Term Debt to Capital stoketherapeutics.com|STOK - Company Cumulative Debt|Debt to Book Value Stoke Therapeutics, Inc.|STOK - Company Long-Term Debts|Company Current Liabilities Stoke Therapeutics|Quick Ratio stoketherapeutics.com
- net income and valuation ratios data:
STOK - Net Financial Result|Projected Future Earnings Stoke Therapeutics|STOK - Price to Earnings Ratio|Future Price to Earnings Stoke Therapeutics Inc|STOK - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Stoke Corp|STOK - Operating income before deduction of amortization|Net earnings per share for the last 12 months Stoke Therapeutics|STOK - Earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months stoketherapeutics.com|STOK - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Stoke Therapeutics
- sales and revenue indicators:
Fundamental company analysis:Stoke Corp
For Stoke Therapeutics (STOK), whose achievements in genetic medicine depend on international patent protection and component logistics, the chart of expected EPS growth for the coming year serves as an indicator of operational resilience. This metric aggregates expert forecasts on net income dynamics, revealing the business's ability to scale without accumulating imbalances, where any downward trend signals a risk of a fundamental drawdown.
Main competitors
TEM (Tempus) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year QGEN (Qiagen)|Earnings growth forecast for next year IONS|RGEN (Repligen) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year aviditybiosciences.com RNA|CRISPR (CRSP) - Expected net earnings per share growth next year|genedx.com - Earnings growth forecast for next year|Expected earnings per share trend next year RARE (ultragenyx.com)|BEAM: Earnings growth forecast for next year|Sarepta - Expected earnings per share trend next year|TWST (twistbioscience.com) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year TXG (10x Genomics Corp)|Earnings growth forecast for next year NTLA|Consensus forecast of earnings per share growth for next year biolifesolutions.com|Earnings growth forecast for next year WVE (Wave Life Sciences Ltd)|Consensus forecast of earnings per share growth for next year Maze Therapeutics (MAZE)|SION: Expected earnings per share growth for next year|Consensus forecast of earnings per share growth for next year Prime Medicine Bio PRME|TSHA: Earnings growth forecast for next year|Projected earnings per share growth rate for next year QURE|Expected earnings per share growth for next year MGTX|Projected earnings per share growth rate for next year RGNX (REGENXBIO)|Earnings growth forecast for next year SLDB|OCGN - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Pacific Biosciences of California PACB|BNTC: Projected earnings per share growth rate for next year|DSGN - Net earnings per share growth forecast for next year|RCKT: Net earnings per share growth forecast for next year|FDMT - Projected earnings per share increase next year|Expected net earnings per share growth next year Lexeo Therapeutics Inc. (LXEO)|Net earnings per share growth forecast for next year Korro Bio Inc.|Editas Medicine (EDIT) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Silence Therapeutics Inc. (SLN)|PRQR: Net earnings per share change forecast for next year|Earnings growth forecast for next year CDXS (codexis.com)|SGMO: Projected earnings per share growth rate for next year|NAUT: Expected earnings per share growth for next year|Expected net earnings per share growth next year metagenomi.co|Precision BioSciences, Inc. (DTIL) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Generation Bio Corp (GBIO)|Expected earnings per share growth for next year BOLD|exicuretx.com (XCUR) - Consensus forecast of earnings per share growth for next year|Expected earnings per share growth for next year IMNN (Celsion Corporation)|PHIO (Phio Pharmaceuticals Corp.) - Expected earnings per share trend next year|Earnings growth forecast for next year MBIO (Mustang Bio Corp)|Projected earnings per share increase next year RNAZ (TransCode Therapeutics)|BNGO - Net earnings per share growth forecast for next year|APDN: Net earnings per share growth forecast for next year|BLUE: Earnings growth forecast for next year|Expected earnings per share growth for next year ImmunoPrecise Antibodies|OMGA (Omega Therapeutics, Inc.) - Earnings growth forecast for next year|Singular Genomics (OMIC) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Regulus (RGLS)|SYRS (Syros Pharmaceuticals, Inc) - Expected earnings per share trend next year|Telesis Bio, Inc. - Expected earnings per share growth for next year|TCON: Projected earnings per share growth rate for next year|Unity Biotechnology Inc. - Earnings growth forecast for next year
